VTv Receives Another U.S. Patent for Its Alzheimer’s Therapy Azeliragon

VTv Receives Another U.S. Patent for Its Alzheimer’s Therapy Azeliragon
VTv Therapeutics has received another U.S. patent for azeliragon, an Alzheimer’s treatment that targets a receptor involved in the disease’s inflammation. Azekuragan is an antagonist of the advanced glycation endproducts, or RAGE, receptor, meaning that it prevents the receptor from acting. Found in low levels in a healthy brain, RAGE numbers increase during inflammation. The patent, number

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *